Infinity Pharmaceuticals, Inc.

2:45 PM - 3:00 PM, Tuesday, June 4,2019 ・ Theater 2
Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing IPI-549, an oral immuno-oncology development candidate that selectively inhibits PI3K-gamma. A Phase 1/1b study in approximately 200 patients with advanced solid tumors is ongoing.
Chair and CEO
Infinity Pharmaceuticals, Inc.